AlphaStocks
6.3
Consider Buy

Dexcom Inc (DXCM)

As of Sep 20, 2026, Dexcom Inc (DXCM) scores 6.3/10 on AlphaStocks' five-model composite, #38 of 168 Health Care stocks. At $89, DXCM trades 58% above its model fair value of $56.

Health Care / Health Care Equipment

S&P 500

$89.36

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#38out of 168 in Health Care

Is DEXCOM INC a Good Investment in 2026?

DEXCOM INC (DXCM) scores 6.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates DEXCOM INC as Strong (7/9). However, the Graham model rates it Caution — Significantly above fair value. DEXCOM INC currently trades 58% above its estimated fair value of $56. DEXCOM INC ranks #38 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E43.3ROE30.6Market Cap35B

Estimated Fair Value

$56.4558% above

Trading above estimated fair value. P/e of 43x implies high growth expectations. rapid eps growth (48%) partially justifies the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Attractive

High PEG — growth premium · Slow Grower

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is DEXCOM INC (DXCM) a good investment?
As of Sep 20, 2026, Dexcom Inc (DXCM) scores 6.3/10 on AlphaStocks' five-model composite, #38 of 168 Health Care stocks. At $89, DXCM trades 58% above its model fair value of $56. That is a middle-of-the-pack score with no strong signal either way.
What is DEXCOM INC's Piotroski F-Score?
DEXCOM INC's Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is DXCM overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $56, DXCM appears overvalued. The stock currently trades 58% above its estimated fair value. Trading above estimated fair value. P/e of 43x implies high growth expectations. rapid eps growth (48%) partially justifies the premium.
How does DXCM compare to other Health Care stocks?
DEXCOM INC ranks #38 out of 168 stocks in the Health Care sector, placing it in the top 23% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about DXCM?
AlphaStocks evaluates DXCM using five proven investment models. Piotroski: Strong; Buffett: Attractive; Graham: Caution; Lynch: Attractive. These models are combined into a single composite score of 6.3/10.

Similar Stocks

INSPUFPTBDX

Compare DXCM with

DXCM vs INSPDXCM vs UFPTBDX vs DXCMDXCM vs VAL

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer